UVA Health is among the few high-volume cardiac care centers in the country with the requisite skills and dedicated expertise to tackle chronic total occlusion. Find out how we achieve high success rates and life-changing outcomes.
Author: Megan Davis (Page 6)
A UVA Health researcher and colleagues have found that a new drug combination may lengthen survival in patients with advanced non-squamous NSCLC.
Discover the new worldwide leader in translational FUS immuno-oncology research.
A team of UVA Health researchers has found evidence that screening for STAT3 mutations will help to better classify and diagnose patients with LGL leukemia.
Serving as a quaternary referral center, we give patients access to innovative procedures and devices only available at select centers.
Hypertrophic cardiomyopathy has historically been less well-understood than other cardiac conditions, but research at UVA Health is opening the door to tailored interventions.
Through a significant investment over 8 years, we became Virginia's first National Cancer Institute-designated comprehensive cancer center.
UVA Health’s facial reanimation program is one of a handful of programs in the U.S. offering the full spectrum of treatments aimed at giving patients with facial paralysis the ability to create more natural facial expressions.
UVA presented live cases at the premier TVT Conference, including a new technique for patients who can’t be helped by standard treatment.
Researchers at UVA Health developed a new heart function measurement that could significantly reduce deaths and hospitalizations from systolic heart failure and pulmonary hypertension.